Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2014

View Archived Issues

Genetic screening to identify novel small-molecule drug targets to overcome drug resistance

Perlstein Lab raises funds for orphan disease drug discovery

Sterigenics completes acquisition of Nordion

Camp Nine changes name to Relmada Therapeutics

Development of a new human monoclonal antibody effective against NiV

ProStrakan completes acquisition of Archimedes Pharma

Data show high efficacy for CF-101 in rheumatoid arthritis and psoriasis

EDP-239 advances into combination studies with alisporivir

Sanofi licenses use of GLAAS platform to develop food allergy therapy

Biodesy enters into research collaboration with Amgen

Eisai reports topline phase III data for eribulin in non-small cell lung cancer

Genentech presents novel series of pan-Pim kinase inhibitors: candidate disclosed

Otsuka Pharmaceutical recaps milestones of first quarter of fiscal 2014

Transplant Genomics reports the development of a transplant surveillance program

Preliminary results from validation study of Oncotype DX prostate cancer test

Lundbeck profiles pipeline progress of second quarter 2014

Merck & Co. patents new BTK inhibitors

Novel anticancer marine macrolides presented by French team

Catalyst Pharmaceutical provides update on phase III Firdapse study

India CSIR discloses new agents for diabetes and dyslipidemia

miRNA biomarkers identified for oesophageal squamous cell carcinoma detection and prognosis

GlaxoSmithKline divulges novel Lp-PLA2 inhibitors

HDAC8 inhibitors patented by U.S. team

Organizations join forces to combat Ebola

Mirati's mocetinostat awarded orphan drug designation for DLBCL

The ALS Association awards 21 new research grants

TapImmune confirms new clinical trial of folate receptor alpha peptide antigens

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...